Novo Nordisk A
Officers & Directors
Helge Lund (born October 1962) served as Chair and Board member from 2017 until stepping down on 14 November 2025. He chaired the People & Governance Committee and the Chair Committee. His external roles included Chair of BP p.l.c., Inkerman AS, and Stiftelsen Værekraft; board member of Belron SA, P/F Tjaldur, and International Crisis Group; and operating advisor to Clayton Dubilier & Rice.
Henrik Poulsen (born September 1967) was Vice Chair and Board member from 2021 until 14 November 2025. He chaired the Remuneration Committee and was a member of the Audit and Chair Committees. Outside the company, he chaired the boards of Carlsberg A/S and Faerch A/S, served on the boards of Novo Holdings A/S (until November 2025) and Bertelsmann SE & Co. KGaA supervisory board, and was a senior advisor to A.P. Møller Holding A/S.
Laurence Debroux (born July 1969) was a Board member from 2019 until 14 November 2025. She chaired the Audit Committee and was a member of the Remuneration Committee. Her external board memberships included Exor N.V., Randstad N.V., Institut Mérieux, HEC Paris Business School, and Kite Insights Limited (until June 2025).
Andreas Fibig (born February 1962) served as a Board member from 2018 until 14 November 2025 and was a member of the Research & Development Committee. Outside the company, he served on the boards of Indigo Agriculture Inc., Evodiabio ApS, and ExlService Holdings, Inc., was honorary director of the German American Chamber of Commerce, and chaired Simtra BioPharma Solutions.
Sylvie Grégoire (born November 1961) was a Board member from 2015 until 14 November 2025. She served on the Audit, Research & Development, and People and Governance Committees. Her external roles included co-founder and board member of CervoMed, Inc., Chair of Abivax SA, board member of F2G Ltd., and advisor to Soffinova Telethon Fund.
Christina Law (born January 1967) was a Board member from 2022 until 14 November 2025 and served on the Audit Committee. Outside the company, she was Group CEO of Raintree Group of Companies and served on the boards of Raintree Group Limited, Raintree Investment Pte Ltd, Air Liquide S.A., La Fondation des Champions, and National Gallery Singapore, where she chaired the development committee.
Martin Mackay (born April 1956) was a Board member from 2018 until 14 November 2025. He chaired the Research & Development Committee and was a member of the Remuneration Committee. Outside the company, he co-founded and was non-executive chair of Rallybio LLC and served on the board of Charles River Laboratories International, Inc., including its science and technology and responsible animal use committees.
Novo Nordisk A currently has 69505 employees.
|
